tucatinib + ramucirumab + paclitaxel

This is a **combination drug regimen** comprising three distinct oncology therapeutics: - **Tucatinib** is a highly selective small molecule inhibitor of *human epidermal growth factor receptor 2* (**HER2**) tyrosine kinase. It blocks oncogenic HER2 signaling in cells with HER2 overexpression, inhibiting cell proliferation and producing antitumor effects. Tucatinib is approved for HER2-positive metastatic breast cancer and is under investigation for HER2-positive gastric, gastroesophageal, and colorectal cancers. - **Ramucirumab** is a fully human monoclonal antibody targeting *vascular endothelial growth factor receptor 2* (**VEGFR2**), blocking ligand binding and thereby inhibiting angiogenesis, which is critical for tumor growth and metastasis. - **Paclitaxel** is a small molecule antineoplastic agent (a taxane), which stabilizes microtubules and inhibits their depolymerization, arresting cells in mitosis and leading to cell death in rapidly dividing cancer cells. This specific three-drug combination is being clinically investigated in Phase 2/3 trials, notably the **MOUNTAINEER-02 study**, for **previously treated HER2-positive gastric or gastroesophageal junction adenocarcinoma**. The regimen is administered in cycles and may also be studied with the addition of trastuzumab. Side effects and efficacy outcomes are being evaluated in ongoing trials[2][5][7][8].

Other names

tucatinibramucirumabpaclitaxel